Endourology
9 cases on adjunct drug therapy for ureteral stent pain on top of existing BPH medication, tranexamic acid before percutaneous nephrolithotomy, periprocedural antithrombotic management across two antithrombotic timelines, antibiotic duration before PCNL, antibiotic selection with a fluoroquinolone contraindication, opioid-sparing analgesia in a solitary kidney, preoperative alpha-blockade before ureteroscopy, desmopressin before a percutaneous renal tract in dialysis, and alkalinizing therapy for stent encrustation — choose a case below to open its full multi-voice debate.
A man on chronic tamsulosin for his prostate now has stent pain from an unrelated stone surgery. The question isn't which drug beats placebo — it's whether a second drug earns its place on top of the one he's already taking.
The transfusion-reduction data for tranexamic acid before a percutaneous kidney tract is real and repeated. So is the fact that its safety record comes almost entirely from patients bleeding for a completely different reason.
Both patients are on drugs that make bleeding worse and stopping them dangerous. What actually divides these two cases isn't the drug class — it's how much time each patient's underlying disease is willing to give before the risk of stopping outweighs the risk of continuing.
Two real bodies of guidance exist for antibiotics before PCNL, and they've never been reconciled. The question is whether this particular patient is the one the longer course was actually built for.
Take away the first-line agent for a real allergy, and the second-line agent for an FDA warning that happens to land exactly on his own physical plans, and what's actually left turns out to matter more than which drug wins on paper.
The trial evidence for opioid-sparing NSAID analgesia after ureteroscopy is genuinely strong. It just wasn't built with anyone in mind who has only one kidney to lose.
Preoperative tamsulosin measurably improves access-sheath placement in trial after trial. The comparator in most of those trials is no drug at all, not a patient whose actual calendar makes a week's delay its own kind of cost.
Nephrology has trusted this drug before a kidney biopsy for forty years. Stone surgery guidelines have never once mentioned it. The needle track is nearly the same either way.
Alkalinizing the urine has real trial support for stopping new stones from forming. A dedicated trial says it doesn't touch stent encrustation at all — and the actual driver of his encrustation hasn't even been identified yet.